Table 1.
Selected PI3K inhibitors in clinical trials
CLL indicates chronic lymphocytic leukemia; NHL, non-HL; PTCL, peripheral T-cell lymphoma; and MM, multiple myeloma.
Selected PI3K inhibitors in clinical trials
CLL indicates chronic lymphocytic leukemia; NHL, non-HL; PTCL, peripheral T-cell lymphoma; and MM, multiple myeloma.
